Legal and Ethical Implications of Peptide Use in Sports

How a Substance Gets on the Prohibited List

Every peptide ban traces back to one short article of the World Anti-Doping Code. Under Article 4.3.1 of the 2021 Code (the version in force as of October 2026), WADA considers a substance for the Prohibited List if, in its sole discretion, it decides the substance meets any two of these criteria:

1. Medical or scientific evidence, pharmacological effect or experience showing that it enhances, or has the potential to enhance, sport performance.
2. Evidence that using it represents an actual or potential health risk to the athlete.
3. WADA's determination that using it violates the spirit of sport.

A separate rule (Article 4.3.2) adds anything that can mask other prohibited substances, with no second criterion needed.

Two features of this test explain most of what follows. First, the word "potential" carries a lot of weight. WADA doesn't need a trial showing that a peptide adds muscle or speeds recovery. A plausible pharmacological effect can satisfy the first criterion, and an unknown safety profile can satisfy the second. Second, Article 4.3.3 makes WADA's decision final. An athlete can't challenge a listing by arguing that a substance doesn't really enhance performance or isn't really risky.

The Code describes the spirit of sport as "the ethical pursuit of human excellence through the dedicated perfection of each Athlete's natural talents," followed by a list of values that begins with health. It's the least measurable criterion, which is why most arguments about peptide bans end up there.

The S0 Catch-All for Unapproved Substances

Most performance peptides were never approved as medicines. S0 (non-approved substances) covers any pharmacological substance that no other section addresses and that has "no current approval by any governmental regulatory health authority for human therapeutic use." WADA's examples range from drugs still in development to veterinary-only products. S0 substances are prohibited at all times.

The link to the criteria is direct. A compound with no approval anywhere has never passed a regulator's review of its human safety, so the health-risk criterion is easy to meet. Add any plausible effect on training or recovery and the test is satisfied without a single performance study.

As of October 2026, WADA's 2026 Prohibited List names BPC-157 in S0 as an example. The 2027 List, which takes effect on January 1, 2027, goes further: according to USADA's athlete advisory, "peptides" in general are now named in the S0 class. USADA also warns that a peptide missing from the List, or from its Global DRO lookup database, may still be prohibited.

S0 has two limits. It applies only when no other section fits, so many peptides people assume are S0 actually sit elsewhere. It also depends on approval status, which can change. Bremelanotide (PT-141) is FDA-approved as Vyleesi, and elamipretide (SS-31) received FDA accelerated approval as Forzinity in 2025, so S0's "no current approval" test no longer clearly applies to either. Neither is named on the 2026 List, and as of October 2026 we couldn't verify whether another section covers them.

A Tale of Two Peptides: The Anabolic vs. The Reparative

Ipamorelin and BPC-157 are both prohibited at all times, but they get there by different routes.

Ipamorelin: banned for what it does

S2.2.4 lists growth hormone releasing factors as a class. Ipamorelin raises growth hormone, and with it IGF-1, the same axis synthetic growth hormone acts on (see how the growth hormone pathway works). For WADA, that pharmacological effect meets the performance criterion.

Human outcome data for this class are thin. In a 2-year randomized trial of MK-677, another oral secretagogue, 65 healthy adults aged 60-81 gained about 1.1 kg of fat-free mass while the placebo group lost a little. Strength and function didn't change. Insulin sensitivity fell. No trial has measured muscle or performance outcomes with ipamorelin itself. Its human record is a dose-escalation study in 48 healthy men and a Phase 2 trial after abdominal surgery that missed its primary endpoint. FDA's 2024 review of that trial reported more low potassium and high blood sugar in the ipamorelin group, plus 2 deaths whose link to the drug was unclear. A clear effect on growth hormone plus a safety signal covers two criteria.

BPC-157: banned for what it is

Users take BPC-157 mostly for tendon and gut problems, not muscle growth, and its WADA case doesn't depend on muscle. A 2025 systematic review in orthopaedic sports medicine found that 35 of 36 eligible studies were preclinical and reported "no clinical safety data." As of October 2026, no controlled human trial has published results. Whether faster healing counts as enhancement is debatable, but under the any-two rule WADA doesn't have to settle that. Missing safety data plus a plausible effect on recovery is enough.

Why "reparative" isn't a safe harbor

Many users assume repair-focused peptides get gentler treatment than anabolic ones. The List says otherwise. TB-500 is a fragment of thymosin beta-4 sold for recovery, yet it isn't in S0 at all. The 2026 List names "Thymosin-ß4 and its derivatives e.g. TB-500" under S2.3, growth factors. That section also reaches growth factor modulators that affect vascularisation or "regenerative capacity", which reads close to a description of what recovery peptides are marketed to do. IGF-1 and its analogues sit in S2.3 too. MOTS-c is named in S4.4.1 as an AMPK activator. As of October 2026, S2 and the S4.3-S4.4 classes are all non-Specified. In WADA's framework, changing how tissue repairs is itself a route to better performance.

What "Specified" Does and Doesn't Mean

BPC-157's Specified status sometimes gets read as WADA calling it a lesser offense. The List quotes the Code's comment against that reading: Specified substances "should not in any way be considered less important or less dangerous" than others. They are simply "more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance." The label matters at the sanctioning stage, not for whether the substance is banned. Detection and sanction lengths are covered in our page on testing exposure and sanctions.

Ethical Implications of the Criteria

Uncertainty counts against the substance. In medicine, a drug has to show benefit before approval. Anti-doping runs the other way: an untested peptide is banned partly because it's untested. Some athletes see this as unfair to compounds that may do nothing. The reasoning behind the health criterion answers that without it, athletes would become the test subjects, and their competitors would feel pressure to join the experiment.

The reason for use doesn't change the listing. The criteria describe the substance, not the user's intent. A lifter using BPC-157 for a stubborn tendon and one hoping to return to heavy training sooner are in the same position. Whether sport should separate recovery from enhancement is a fair question, and our companion piece on the recovery-versus-enhancement debate works through it. For genuine medical need, the Code's route is the Therapeutic Use Exemption (Article 4.4), decided case by case.

The spirit-of-sport criterion is a judgment call. Performance effects and health risks can, in principle, be measured. The spirit of sport can't, and Article 4.3.3 means it can't be litigated either. That puts a lot of trust in WADA's expert process, which takes comments on the List from governments and other stakeholders each year.

Approval is a proxy, and proxies can shift. PT-141 and SS-31 show that a compound can move out of S0's reach because a regulator approved it for an unrelated condition, without any new evidence about sport. Using approval as a stand-in for known safety is practical, but it ties a peptide's status to decisions made for other reasons.

Outside tested sport, the health reasoning still applies. The List has no force for someone who doesn't compete in a tested federation, but the logic behind S0 still describes their situation: a compound with no long-term human safety data. Drug law is a separate system, covered in our page on how FDA rules differ from WADA bans.

What to Watch Next

• The 2027 List takes effect on January 1, 2027. USADA reports that it names "peptides" in the S0 class; we haven't yet checked the final wording against WADA's own 2027 document.
• Approved peptides. Whether WADA names elamipretide or bremelanotide in a specific section now that both are approved drugs.
• GLP-1 drugs. As of October 2026, semaglutide and tirzepatide are not prohibited. Both stay in WADA's 2027 Monitoring Program, which tracks substances WADA wants to learn more about. Adding them to the List would still require two of the three criteria.